Literature DB >> 16847266

Genes and pathways downstream of telomerase in melanoma metastasis.

Sepideh Bagheri1, Mehdi Nosrati, Shang Li, Sylvia Fong, Sima Torabian, Javier Rangel, Dan H Moore, Scot Federman, Rebecca R Laposa, Frederick L Baehner, Richard W Sagebiel, James E Cleaver, Christopher Haqq, Robert J Debs, Elizabeth H Blackburn, Mohammed Kashani-Sabet.   

Abstract

Recent studies have demonstrated a role for telomerase in driving tumor progression, but its mechanism of action remains unclear. Here we show that stable, ribozyme-mediated suppression of mouse telomerase RNA reduced telomerase RNA expression, telomerase activity, and telomere length, which significantly reduced tumor invasion and metastatic potential. Our studies reveal that previously unidentified effects of telomerase may mediate its tumor-promoting effects. First, reducing telomerase activity induced a more dendritic morphology, accompanied by increased melanin content and increased expression of tyrosinase, a key enzyme in melanin biosynthesis. Second, gene expression profiling revealed that telomerase targeting down-regulated expression of several glycolytic pathway genes, with a corresponding decrease in glucose consumption and lactate production. Thus, telomerase activity controls the glycolytic pathway, potentially altering the energy state of tumor cells and thereby modulating tyrosinase activity and melanin production. These studies have important implications for understanding the mechanisms by which telomerase promotes tumor invasion and metastasis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16847266      PMCID: PMC1544082          DOI: 10.1073/pnas.0510085103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

1.  Telomere states and cell fates.

Authors:  E H Blackburn
Journal:  Nature       Date:  2000-11-02       Impact factor: 49.962

2.  The melanocyte differentiation program predisposes to metastasis after neoplastic transformation.

Authors:  Piyush B Gupta; Charlotte Kuperwasser; Jean-Philippe Brunet; Sridhar Ramaswamy; Wen-Lin Kuo; Joe W Gray; Stephen P Naber; Robert A Weinberg
Journal:  Nat Genet       Date:  2005-09-04       Impact factor: 38.330

3.  Cellular and gene expression responses involved in the rapid growth inhibition of human cancer cells by RNA interference-mediated depletion of telomerase RNA.

Authors:  Shang Li; Julia Crothers; Christopher M Haqq; Elizabeth H Blackburn
Journal:  J Biol Chem       Date:  2005-04-13       Impact factor: 5.157

4.  The gene expression signatures of melanoma progression.

Authors:  Christopher Haqq; Mehdi Nosrati; Daniel Sudilovsky; Julia Crothers; Daniel Khodabakhsh; Brian L Pulliam; Scot Federman; James R Miller; Robert E Allen; Mark I Singer; Stanley P L Leong; Britt-Marie Ljung; Richard W Sagebiel; Mohammed Kashani-Sabet
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-15       Impact factor: 11.205

5.  Creation of human tumour cells with defined genetic elements.

Authors:  W C Hahn; C M Counter; A S Lundberg; R L Beijersbergen; M W Brooks; R A Weinberg
Journal:  Nature       Date:  1999-07-29       Impact factor: 49.962

6.  Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase.

Authors:  A J Lay; X M Jiang; O Kisker; E Flynn; A Underwood; R Condron; P J Hogg
Journal:  Nature       Date:  2000-12-14       Impact factor: 49.962

7.  Proper folding and endoplasmic reticulum to golgi transport of tyrosinase are induced by its substrates, DOPA and tyrosine.

Authors:  R Halaban; E Cheng; S Svedine; R Aron; D N Hebert
Journal:  J Biol Chem       Date:  2000-12-20       Impact factor: 5.157

Review 8.  Why do cancers have high aerobic glycolysis?

Authors:  Robert A Gatenby; Robert J Gillies
Journal:  Nat Rev Cancer       Date:  2004-11       Impact factor: 60.716

9.  Autocrine motility factor signaling enhances pancreatic cancer metastasis.

Authors:  Soichi Tsutsumi; Takashi Yanagawa; Tatsuo Shimura; Hiroyuki Kuwano; Avraham Raz
Journal:  Clin Cancer Res       Date:  2004-11-15       Impact factor: 12.531

10.  Telomerase activity in human acute myelogenous leukemia: inhibition of telomerase activity by differentiation-inducing agents.

Authors:  W Zhang; M A Piatyszek; T Kobayashi; E Estey; M Andreeff; A B Deisseroth; W E Wright; J W Shay
Journal:  Clin Cancer Res       Date:  1996-05       Impact factor: 12.531

View more
  48 in total

1.  Genetic variations in TERT-CLPTM1L genes and risk of squamous cell carcinoma of the head and neck.

Authors:  Zhensheng Liu; Guojun Li; Sheng Wei; Jiangong Niu; Li-E Wang; Erich M Sturgis; Qingyi Wei
Journal:  Carcinogenesis       Date:  2010-08-28       Impact factor: 4.944

Review 2.  Friend or foe? Telomerase as a pharmacological target in cancer and cardiovascular disease.

Authors:  Karima Ait-Aissa; Johnathan D Ebben; Andrew O Kadlec; Andreas M Beyer
Journal:  Pharmacol Res       Date:  2016-07-06       Impact factor: 7.658

3.  Integrated nanosensors to determine levels and functional activity of human telomerase.

Authors:  J Manuel Perez; Jan Grimm; Lee Josephson; Ralph Weissleder
Journal:  Neoplasia       Date:  2008-10       Impact factor: 5.715

4.  Quantification of hTERT splice variants in melanoma by SYBR green real-time polymerase chain reaction indicates a negative regulatory role for the beta deletion variant.

Authors:  Lisa F Lincz; Lisa-Maree Mudge; Fiona E Scorgie; Jennette A Sakoff; Christopher S Hamilton; Michael Seldon
Journal:  Neoplasia       Date:  2008-10       Impact factor: 5.715

5.  Enhanced migration and CXCR4 over-expression in fibroblasts with telomerase reconstitution.

Authors:  Yi Qu; Meng Mao; Xihong Li; Lin Zhang; Xiang Huang; Chunlei Yang; Fengyang Zhao; Ying Xiong; Dezhi Mu
Journal:  Mol Cell Biochem       Date:  2008-03-25       Impact factor: 3.396

6.  Ribozyme-mediated targeting of IkappaBgamma inhibits melanoma invasion and metastasis.

Authors:  Sima Z Torabian; David de Semir; Mehdi Nosrati; Sepideh Bagheri; Altaf A Dar; Sylvia Fong; Yong Liu; Scot Federman; Jeff Simko; Chris Haqq; Robert J Debs; Mohammed Kashani-Sabet
Journal:  Am J Pathol       Date:  2009-01-29       Impact factor: 4.307

7.  Cancer as a metabolic disease.

Authors:  Thomas N Seyfried; Laura M Shelton
Journal:  Nutr Metab (Lond)       Date:  2010-01-27       Impact factor: 4.169

8.  Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms.

Authors:  Sarah K Brennan; Qiuju Wang; Robert Tressler; Calvin Harley; Ning Go; Ekaterina Bassett; Carol Ann Huff; Richard J Jones; William Matsui
Journal:  PLoS One       Date:  2010-09-01       Impact factor: 3.240

9.  Telomere shortening sensitizes cancer cells to selected cytotoxic agents: in vitro and in vivo studies and putative mechanisms.

Authors:  Orit Uziel; Einat Beery; Vladimir Dronichev; Katty Samocha; Sergei Gryaznov; Lola Weiss; Shimon Slavin; Michal Kushnir; Yardena Nordenberg; Claudette Rabinowitz; Baruch Rinkevich; Tania Zehavi; Meir Lahav
Journal:  PLoS One       Date:  2010-02-09       Impact factor: 3.240

10.  Comparing effects of mTR and mTERT deletion on gene expression and DNA damage response: a critical examination of telomere length maintenance-independent roles of telomerase.

Authors:  Sofia L Vidal-Cardenas; Carol W Greider
Journal:  Nucleic Acids Res       Date:  2009-10-22       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.